| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (HHS) CRUSSH | Stereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trial | Donovan, Dr Elysia | Open to recruitment | NCT03529708 |
| (Tesaro) 4010-01-001 / GARNET | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | Elit, Dr Laurie | Open to recruitment | NCT02715284 |
| (Debio) 1143-NSCLC-105 | A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapy | Juergens, Dr Rosalyn | Open to recruitment | NCT03270176 |
| (UHN) OCTANE | Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) | Hotte, Dr Sebastien | Suspended/On hold | NCT02906943 |
| (Roche) NP39487 | OPEN-LABEL, DOSE FINDING AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF RO6870810 AND ATEZOLIZUMAB (PD-L1 ANTIBODY) IN PATIENTS WITH ADVANCED OVARIAN CANCER OR TRIPLE NEGATIVE BREAST CANCER | Hirte, Dr Hal | Suspended/On hold | NCT03292172 |
| (AstraZeneca) D4191C00068 / STRONG | An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol; Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract | Hotte, Dr Sebastien | Suspended/On hold | NCT03084471 |
Find a Trial
Contact Us